Crystalys Therapeutics has dosed the first patient with its once daily oral, URAT1 inhibitor dotinurad in its Phase II AMETHYST trial (NCT07535034), designed to assess dotinurad’s effectiveness in ...

Aarti Pharmalabs Ltd (BOM:543748) reported a 9% year-over-year increase in Q4 revenue, reaching Rs 580 crore. The Xanthine derivative segment achieved its highest-ever quarterly revenue, contributing ...

Crystalys Therapeutics Inc. ('Crystalys' or 'the Company'), a clinical-stage biopharmaceutical company addressing the significant unmet medical needs of people living with gout, today announced that ...

Track Aarti Pharmalabs share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, shareholding, financial reports, annual & quarterly results, and profit & ...

Sun and colleagues identify CLEC12B as a natural killer (NK) cell inhibitory checkpoint that limits antitumor immunity. They also develop a nanobody to target CLEC12B, activating NK cell killing of ...